A5067427854- Nutrition, Genetics, and Disease
- BRCA gene mutations in cancer
- Epigenetics and DNA Methylation
- CRISPR and Genetic Engineering
- Histiocytic Disorders and Treatments
- Ovarian cancer diagnosis and treatment
- Tumors and Oncological Cases
- Molecular Biology Techniques and Applications
- RNA Research and Splicing
- PARP inhibition in cancer therapy
- Mast cells and histamine
Institut Gustave Roussy
2022-2025
Inserm
2022
Abstract Purpose: Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade cancer clinical behavior assess its relevance. Experimental Design: This a retrospective monocentric analysis centrally tested for genomic instability score (GIS) by MyChoice CDx (Myriad Genetics). detection...
Malignant histiocytoses (MH) are rare and poorly understood cancers, with no established therapeutic guidelines. We conducted a national retrospective study of MH diagnosed in France between 2000 2023. All cases underwent centralized histological review, several malignant tumors stroma highly enriched histiocytes were excluded. In total, 141 patients included, median age 62 years (range, 1 to 87 years). The comprised either primary (64%) or associated other hematologic malignancies (36%)....
<div>Abstract<p>Purpose: Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade OC clinical behavior assess its relevance. Design: This a retrospective monocentric analysis centrally tested for genomic-instability score (GIS) by MyChoice CDx (Myriad Genetics). detection quantification were...
<div>Abstract<p>Purpose: Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade OC clinical behavior assess its relevance. Design: This a retrospective monocentric analysis centrally tested for genomic-instability score (GIS) by MyChoice CDx (Myriad Genetics). detection quantification were...
<div>AbstractPurpose:<p>Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of <i>BRCA1</i> promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade cancer clinical behavior assess its relevance.</p>Experimental Design:<p>This a retrospective monocentric analysis centrally tested for genomic instability score (GIS) by...
<div>AbstractPurpose:<p>Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of <i>BRCA1</i> promoter methylation predict prognosis and HRD status remains unclear. We aimed correlate levels patients with high-grade cancer clinical behavior assess its relevance.</p>Experimental Design:<p>This a retrospective monocentric analysis centrally tested for genomic instability score (GIS) by...